Enteric-Coated Capsule with Cationic Nanoparticles for Oral Insulin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for oral insulin delivery face challenges such as rapid enzymatic degradation and poor intestinal absorption due to gastrointestinal barriers, with existing nanoparticles often exhibiting non-synergistic properties that compromise stability and absorption efficiency.
Innovation Solution
Development of an enteric-coated capsule containing cationic nanoparticles with a polycationic polymer, biodegradable polymer, and stabilizer, designed for pH-sensitivity and mucoadhesivity, which opens tight junctions in the small intestine for enhanced insulin absorption, using Eudragit RS and PLGA with a pH-sensitive coating layer for controlled release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral insulin delivery is used, then patient compliance and convenience are improved, but insulin undergoes rapid enzymatic degradation and poor intestinal absorption
Solution Approach 1:
The delivery system is segmented into two distinct components: an enteric-coated capsule shell that protects insulin during gastric transit, and cationic nanoparticles that facilitate intestinal absorption. This segmentation allows each component to specialize in overcoming specific barriers, with the capsule providing macro-level protection and nanoparticles enabling micro-level cellular uptake, thereby maintaining insulin stability while improving oral delivery efficacy
Solution Approach 2:
The invention employs composite materials at multiple levels: the enteric coating combines pH-sensitive polymers to create a barrier against gastric acid; the nanoparticles use cationic polymers combined with stabilizing agents to protect insulin from enzymatic degradation; and the overall system integrates these composite structures to simultaneously address stability and absorption challenges, transforming the harmful GI environment into a controlled delivery pathway
2Productivity
If polycationic nanoparticles are used to enhance intestinal absorption, then mucoadhesivity and permeability are improved, but nanoparticle stability in the stomach is reduced
Solution Approach 1:
The enteric coating is applied preliminarily to the capsule before nanoparticle administration, creating a protective barrier that pre-prevents gastric acid damage to the cationic nanoparticles. This preliminary protective action allows the nanoparticles to maintain their positive charge and structural integrity during gastric transit, ensuring they remain stable until they reach the intestinal environment where absorption is needed
Solution Approach 2:
The system exhibits dynamic behavior through pH-responsive switching: the enteric coating remains intact in acidic gastric pH to protect nanoparticles, then dynamically dissolves in neutral intestinal pH to release the nanoparticles. This dynamic transformation allows the same nanoparticle formulation to be stable in the stomach (when protected) and highly active in the intestine (when released), resolving the contradiction between stability and absorption efficiency
3Stability of the object's composition
If pH-sensitive nanoparticles are used to protect from stomach acidity, then gastric protection is improved, but positive charge for absorption is weakened
Solution Approach 1:
The invention separates the protection function and absorption function into different spatial and temporal dimensions: the enteric coating provides protection in the gastric dimension (acidic environment), while the nanoparticles provide absorption in the intestinal dimension (neutral environment). This dimensional separation allows pH-sensitive properties to serve protection without compromising absorption, as the charge modification occurs only after the nanoparticles reach the appropriate intestinal pH environment
4Ease of operation
If insulin nanoparticles are administered orally, then convenience is improved, but enzymatic degradation and poor absorption occur
Solution Approach 1:
The system utilizes parameter changes in pH along the GI tract to control insulin delivery: the enteric coating is designed to be stable at gastric pH (protection mode) and dissolve at intestinal pH (release mode). This parameter-based control ensures that insulin remains protected during gastric transit and is released in sufficient quantities at the absorption site, maintaining bioavailability while preserving oral administration convenience
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enteric-coated capsule effectively protects insulin from stomach acidity and enhances intestinal absorption, achieving a controlled and prolonged release of insulin, demonstrating a synergistic effect in overcoming gastrointestinal barriers and improving bioavailability.
Implementation Method 1
The enteric-coated capsule is sensitive to pH change, and can therefore dissolve rapidly in the upper region of the small intestine
Implementation Method 2
The nanoparticles having a more positive charge are more effective on opening tight junctions, leading to an increase in paracellular permeability
Implementation Method 3
Special pH-sensitivity of nanoparticles provides the protection to confront this first barrier by preventing insulin from contacting the highly acidic medium in the stomach
Data Source
AI summary
The invention relates to an enteric-coated capsule containing cationic nanoparticles for oral insulin delivery, in particular to a type of cationic nanoparticle including a polycationic and mucoadhesive polymer and a biodegradable polymer, wherein each of the nanoparticles has positive surface charge and enhanced permeability for paracellular insulin delivery; the enteric-coated capsule further includes a pH-sensitive polymer as the coating. The enteric-coated capsule containing cationic nanoparticles, when being orally administered to a subject, are configured to prevent the acidic degradation of the active substance such as insulin before being released from said cationic nanoparticles to a specific absorption site along the gastrointestinal tract.